PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

PVI, PeerView Institute for Medical Education

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

All Episodes

Go online to PeerView.com/AZH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in eosinophilic esophagitis discusses the latest research, data, and guidelines on novel and emerging targeted therapies. Upon completion of this CE activity, participants will be able to: Interpret recent developments in clinical research and treatment guidelines regarding the management of eosinophilic esophagitis (EoE), Employ the latest clinical data, including evidence concerning novel and emerging targeted therapies, into treatment plans for the management of patients with EoE as they become available.

Nov 23

19 min 26 sec

Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct a thorough medical history to guide the selection of adequate and relevant tests for the diagnostic workup in CSU, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Evaluate recent clinical trial data related to novel treatment options for CSU, Treat CSU in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from newer therapeutic options.

Nov 19

22 min 9 sec

Go online to PeerView.com/RSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert dermatologist discusses the latest evidence from the 30th European Academy of Dermatology and Venereology Congress for current and emerging targeted biologic therapies for moderate to severe atopic dermatitis in adults and children. Upon completion of this accredited CE activity, participants should be better able to: Interpret recent developments in clinical research and treatment guidelines regarding the management of pediatric and adult patients with moderate to severe atopic dermatitis, Apply the latest clinical evidence on approved and emerging biologic therapies into personalized treatment plans for pediatric and adult patients with moderate to severe atopic dermatitis.

Nov 3

25 min 17 sec

Go online to PeerView.com/BQR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live satellite symposium held at HFSA 2021, expert faculty review the evidence for current and emerging treatment strategies for hypertrophic cardiomyopathy (HCM) using patient cases to illustrate the ways in which clinicians can adapt current practices and utilize shared decision-making to offer appropriate treatment options to patients with HCM. Upon completion of this activity, participants should be better able to: Recognize HCM’s pathophysiology and the associated disease burdens that may be experienced by patients (eg, health impact, quality of life, daily activities), Apply the latest recommendations and guidance for diagnosing, evaluating, and monitoring patients with HCM in a team-based manner, Evaluate current and emerging strategies for managing HCM in terms of efficacy, safety, and effects on burden of disease, Collaborate with patients to identify their individual goals and counsel them about the benefits and risks of testing and treatment.

Oct 19

51 min 26 sec

Go online to PeerView.com/DWM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pulmonology discusses the latest clinical research and treatment guidelines on approved biologic therapies for the management of adult and pediatric patients with uncontrolled moderate to severe asthma. Upon completion of this accredited CE activity, participants should be better able to: Explain to peers the latest developments in clinical research and treatment guidelines with regard to the use of currently approved targeted therapy for the management of adult and pediatric patients with uncontrolled moderate to severe asthma, Integrate recent clinical research findings on approved biologic therapies into personalized treatment plans for adult and pediatric patients with uncontrolled moderate to severe asthma.

Oct 12

34 min 11 sec

Go online to PeerView.com/PGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in blood and marrow transplantation illuminate the roles of various members of the transplant team in the overall approach to diagnosing and treating VOD/SOS, while also offering learners a window into how hematologist-oncologists, transplant specialists, advanced practice clinicians, radiologists, pathologists, nurses, pharmacists, and other team members can collaborate to overcome the many challenges of VOD/SOS. Upon completion of this activity, participants should be better able to: Explain the clinical signs, symptoms, and medical burden of VOD/SOS to patients preparing for transplantation, Apply team-based approaches to risk assessment and diagnostic confirmation of VOD/SOS, including interpretation of clinical symptoms/disease onset and use of techniques such as ultrasound imaging or other strategies as appropriate, Use modern adverse event severity grading models to determine the presence and severity of organ dysfunction in patients with a VOD/SOS diagnosis, Recommend appropriate team management options for adult and pediatric patients with VOD/SOS in the post-HCT setting.

Oct 11

51 min 32 sec

Go online to PeerView.com/FXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses new and emerging therapies for patients with moderate to severe atopic dermatitis. Upon completion of this accredited CE activity, participants should be better able to: Describe key cytokine signaling pathways involved in the pathogenesis of atopic dermatitis (AD) and implications for treatment, Evaluate recent clinical trial data related to the efficacy and safety of new and emerging treatment options (eg, JAK inhibitors) for moderate to severe AD, Treat AD in accordance with current evidence and guidelines, identifying patients with moderate to severe disease who would likely derive benefit from novel therapeutic options, Discuss evidence and recommendations on the immunization and monitoring of patients with AD who are candidates for, or receiving, biological or small-molecule targeted immunomodulatory therapies.

Oct 1

27 min 58 sec

Go online to PeerView.com/GZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two melanoma experts engage in case-based discussions and scientific lecture segments on topics such as the selection of immunotherapy in metastatic disease, best practices for the use of adjuvant or neoadjuvant checkpoint blockade, and how future care will be defined by emerging science on novel immunotherapy combination approaches. Upon completion of this accredited CE activity, participants should be better able to: Cite current evidence and guideline recommendations for the use of immunotherapy in resectable stage III/IV melanoma and unresectable, metastatic disease, Summarize evidence on novel applications of immunotherapy in melanoma, including as neoadjuvant therapy, as an adjuvant option for stage II disease, or as part of novel combinatorial approaches, Integrate immunotherapy into the management of patients with resectable and unresectable melanoma, including those with BRAF-positive or BRAF-negative disease, Manage immune-related adverse events in patients with melanoma receiving immunotherapy across the spectrum of disease.

Jul 16

1 hr 5 min

Go online to PeerView.com/FXM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses the latest evidence on novel cytokine-modulating strategies in the treatment of moderate to severe psoriasis. Upon completion of this accredited CE activity, participants should be better able to: Recognize unmet needs in the treatment of moderate to severe psoriasis, Describe the pathophysiology of psoriasis, recognizing current and emerging targets for therapeutic intervention, Summarize efficacy and safety data related to nonbiologic oral therapies and novel cytokine inhibitors for the treatment of moderate to severe psoriasis, Treat moderate to severe psoriasis in accordance with current evidence and individual patient needs, identifying those who would likely derive benefit from novel therapeutic options.

Jul 2

28 min 34 sec

Go online to PeerView.com/NJS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses unmet needs of patients with moderate to severe psoriasis and the clinical potential of targeting the TYK2 pathway as a novel nonbiologic oral therapeutic option. Upon completion of this accredited CE activity, participants should be better able to: Explain the role of the JAK-STAT signaling pathway in the pathophysiology of psoriasis, Summarize efficacy and safety data related to current and emerging kinase inhibitors for the treatment of psoriasis, Treat moderate to severe psoriasis in accordance with current evidence and guidelines, recognizing the role of nonbiologic therapies in addressing the burden of disease and comorbidities in individual patients.

Jun 25

37 min 40 sec

Go online to PeerView.com/NZQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy currently has a role as consolidation therapy after chemoradiation for patients with stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC). Other agents and strategies are being explored in the locally advanced setting as well. Many clinical trials are also investigating the use of immune checkpoint inhibitors as neoadjuvant and adjuvant systemic therapies in earlier stages of NSCLC, and promising data have started to emerge, including from the first few phase 3 studies. With the continual expansion of immunotherapy into earlier disease settings, multidisciplinary collaboration among thoracic surgeons, medical oncologists, radiation oncologists, and the greater lung cancer care team is paramount. This PeerView Live Seminar and Practicum based on a recent live web broadcast explores the latest advances and clinical trial findings with immunotherapies, analyzes implications for surgical management of patients, and provides case-based, practical guidance for integrating immunotherapies into multimodal management of stage I-III NSCLC in the context of multidisciplinary care. Upon completion of this accredited CE activity, participants should be better able to: Characterize the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies, and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, Discuss the current and evolving immunotherapy landscape and state of the science in lung cancer, including in locally advanced and earlier stages of NSCLC, Review key clinical trials assessing immunotherapies and immune-based combinations in stage III and earlier stages of lung cancer, and available data from such trials, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Determine the best treatment approaches for patients with stage III or earlier lung cancer as part of clinical practice or clinical trials based on the latest evidence, recommendations, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care.

Jun 22

1 hr 10 min

Go online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in clinical use or showing promise. However, many research questions and practical challenges remain about biomarker testing, scoring, and interpretation in different tumors to identify patients who are most likely to benefit from cancer immunotherapies. This PeerView Clinical and Laboratory Accelerator based on a recent web broadcast provides practical guidance for navigating the complexities of cancer immunotherapy biomarker testing. Oncology and pathology experts focus on the nuances of PD-L1 expression assessment, along with other relevant biomarkers, in different solid tumors and how to use this information to direct clinical decisions regarding treatment selection for appropriate patients. Ongoing research efforts and innovations to refine and expand the role of cancer immunotherapy biomarkers are explored as well. Upon completion of this accredited CE activity, participants should be better able to: Assess the latest evidence on PD-L1 as a pan-tumor biomarker and the rationale for its use to predict benefit from cancer immunotherapies, Analyze practical considerations and complexities of PD-L1 biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, standardization/harmonization options, cut points, digital pathology, artificial intelligence/machine learning, and other nuances, Incorporate the latest evidence and recommendations for PD-L1 biomarker testing in clinical and laboratory settings across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to optimize the selection and interpretation of PD-L1 biomarker testing to guide clinical decision-making.

Jun 21

1 hr 33 min

Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

Jun 18

27 min 5 sec

Go online to PeerView.com/HKY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert in the management of acute hepatic porphyria (AHP) discusses recent evidence and recommendations for treating AHP and highlights the rationale and role of a new siRNA-based therapeutic option. Upon completion of this activity, participants should be better able to: Recognize AHP and associated disease burdens that may be experienced by patients (eg, health impact, quality of life, daily activities), Describe evidence-based interventions for AHP, including the rationale and trial data for recently approved siRNA therapy, Apply evidence-based diagnostic and treatment approaches to minimize disease impact and burden for individuals with AHP.

Jun 2

31 min 57 sec

Go online to PeerView.com/KQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The management of patients with non–small cell lung cancer (NSCLC) is exemplary of precision medicine. Extensive and nuanced genomic profiling of NSCLC is essential to inform individualized treatment plans to optimize patient outcomes. Currently, there are seven different molecular alterations for which FDA-approved targeted therapies are available: EGFR, ALK, ROS1, BRAF V600E, NTRK, MET exon 14, and RET. With the growing complexity of the targeted therapeutic landscape of lung cancer, it is imperative that members of the multidisciplinary care team maintain best practices regarding genomic testing to effectively incorporate targeted therapies into clinical practice. This PeerView educational activity based on a recent web broadcast provides practical guidance for navigating the continuing wave of predictive genomic alterations and related matched therapies, uniting pathologists with oncologists and other multidisciplinary specialists to ensure that patients with genomically altered NSCLC receive appropriate testing and therapy. Upon completion of this activity, participants should be better able to: Discuss the expanding role and increasing importance of broad molecular testing for identifying patients with NSCLC who have therapeutically targetable molecular alterations, Describe the molecular alterations that are clinically relevant and therapeutically targetable in NSCLC, and the latest testing methods for identifying these alterations, Analyze data from clinical trials of precision therapies that target key molecular alterations in NSCLC, Implement best practices and collaborative strategies for integration of wide-spread molecular testing to ensure that patients with NSCLC receive the most appropriate therapies in the context of clinical practice or clinical trials.

Jun 1

1 hr 7 min

Go online to PeerView.com/BFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME/MOC/CC/NCPD-accredited activity, a hematologist-oncologist, a pathologist, and a physician assistant team up to discuss a collaborative approach to managing their patients with high-risk myeloid cancers, such as acute myeloid leukemia and myelodysplastic syndrome. Hear how Naval Daver, MD, Sanam Loghavi, MD, and Megan Wiese, PA-C, from the MD Anderson Cancer Center, collaborate on diagnosis, treatment decision-making, safety management, and patient education, with the ultimate goal of providing the best care for their patients. Upon completion of this activity, participants will be able to: Discuss the clinical signs and diagnostic principles of high-risk myeloid cancers, including TP53-mutant disease, Summarize current evidence related to the efficacy and safety of novel strategies for the management of high-risk acute myeloid leukemia or myelodysplastic syndromes, Develop team-based diagnostic, treatment, and safety management plans for patients presenting with high-risk myeloid cancers, Apply team-based educational interventions detailing prognostic and therapeutic expectations for patients with high-risk acute myeloid leukemia or myelodysplastic syndromes.

May 28

54 min 4 sec

Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management. Upon completion of this activity, participants should be better able to: Identify disease- and patient-related factors that can guide therapeutic selection and prognosis in patients with follicular lymphoma, Summarize current safety and efficacy evidence surrounding novel targeted agents in the setting of relapsed/refractory follicular lymphoma, Integrate targeted agents into the management of patients with relapsed follicular lymphoma, Develop a management plan for the unique adverse events associated with the use of novel therapies in the follicular lymphoma setting.

May 14

35 min 25 sec

Go online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should inform the prevention and treatment of this disease in hematopoietic stem cell transplant recipients. Upon completion of this activity, participants should be better able to: Describe the pathogenesis of post-HCT GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD; Summarize current data surrounding innovative therapies for the prevention or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HCT setting; Integrate approved and emerging therapies into treatment plans, including clinical trial enrollment, for post-HCT GVHD care based on individual patient and disease characteristics.

Apr 8

53 min 19 sec

Go online to PeerView.com/MME860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelofibrosis (MF) is a rare myeloproliferative neoplasm which can lead to marrow fibrosis, neo-angiogenesis, and osteosclerosis causing progressive splenomegaly with or without hepatomegaly. Currently, the only potential cure for MF is hematopoietic cell transplantation (HCT). However, the emergence and validation of JAK inhibitors has impacted treatment decisions, including the timing of HCT, and newer evidence suggests that next-generation JAK inhibitors may also play a role in challenging treatment settings defined by failure of upfront JAK inhibitor therapy. Clinicians therefore should be prepared to develop truly personalized, newer therapeutic strategies for MF management that consider all available options—from targeted agents to supportive care, as well as HCT—and address the role of JAK inhibitors in patients who are transplant candidates and determine their role before and, possibly, after transplantation. In this activity based on a recent live web broadcast, a panel of experts describes the current therapeutic landscape of MF, including JAK inhibitors and HCT. They also review evidence supporting the use of first- and second-generation JAK inhibitors and other targeted agents in MF. Upon completion of this activity, participants should be better able to: Describe modern diagnostic and prognostic models, as well as molecular and clinical features that are useful for capturing myelofibrosis (MF) presentations, including primary MF and post-PV/ET MF, Review the current therapeutic role of JAK inhibitors and allogeneic hematopoietic cell transplantation (HCT), including reduced-intensity transplant, in the management of MF, Cite recent safety and efficacy evidence supporting the use of first- and second-generation JAK inhibitors and other targeted agents in the management of MF, Integrate modern JAK inhibitor-based regimens into risk-adapted treatment plans for patients with symptomatic MF, including those who are eligible for allogeneic transplantation or as sequential options in the non-HCT setting.

Mar 26

58 min 11 sec

Go online to PeerView.com/ERM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in chronic rhinosinusitis with nasal polyps (CRS/NP) discusses how to diagnose and manage CRS/NP; identifies patients with severe, inadequately controlled CRS/NP to determine eligibility for targeted biologic therapy; and discusses treatment plans for patients with CRS/NP according to international consensus statements and the latest clinical evidence as part of a multidisciplinary approach. Upon completion of this activity, participants should be better able to: Describe the burden that chronic rhinosinusitis with nasal polyps (CRS/NP), including certain treatment measures, such as surgery, may have on patient quality of life, Identify patients with severe, inadequately controlled CRS/NP to determine eligibility for targeted biologic therapy, Develop treatment plans for patients with CRS/NP according to practice guidelines and the latest clinical evidence as part of a multidisciplinary approach.

Mar 24

34 min 39 sec

Go online to PeerView.com/CAV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an immuno-oncology expert describes the benefits and limitations of available immune checkpoint inhibitors, investigational immunotherapies, and rational combinations that may expand the therapeutic landscape for various malignancies, and explains how to integrate the latest immunotherapy approaches into cancer care in the context of clinical practice or ongoing studies. Upon completion of this activity, participants should be better able to: Summarize the benefits and limitations of available immune checkpoint inhibitors and the need for novel immunotherapies and combinations to optimize outcomes for patients with cancer, Discuss investigational immunotherapies and rational combinations that may be able to expand on the current therapies or overcome immune evasion and resistance, Integrate the latest immunotherapy approaches into cancer care in the context of clinical practice or clinical trials.

Mar 22

39 min 1 sec

Go online to PeerView.com/MSE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is an aggressive form of lung cancer that lacked treatment advances for more than three decades. Fortunately, immune checkpoint inhibitors have recently revolutionized the extensive-stage (ES) SCLC treatment landscape, and combination chemoimmunotherapy has become the new standard of care in the first-line setting. Research efforts are continuing to refine and expand the role of immunotherapies in SCLC. To make the most of this novel therapeutic approach, it is essential for oncology professionals as well as the broader multidisciplinary team of professionals to keep up with the latest therapeutic advances and collaborate effectively to establish the diagnosis, ensure a rapid initiation of therapy, and appropriately manage potential immune-related adverse events. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. Leading experts provide an engaging educational session on the latest science, best practices, and multidisciplinary implications related to integrating cancer immunotherapies into the management plans for patients with ES-SCLC. Upon completion of this activity, participants will be able to: Describe the epidemiology, clinical features, and current treatment of extensive-stage small cell lung cancer (ES-SCLC), including immunotherapies that can improve long-term outcomes, Examine the latest efficacy, safety, and biomarker data from clinical trials evaluating available and emerging immunotherapies and immune-based combinations for ES-SCLC, Implement optimal strategies for screening, diagnosing, and staging of patients with lung cancer to ensure timely and accurate diagnosis, prompt oncology referral, and rapid treatment initiation for patients with ES-SCLC, Apply best practices for collaboration and coordination of care with oncologists and other members of the multidisciplinary lung cancer team to provide optimal care to patients with ES-SCLC, including the integration of immunotherapies into treatment plans and recognition/management of irAEs, and improve outcomes.

Mar 10

1 hr 3 min

Go online to PeerView.com/ATX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new multiple myeloma (MM) CME program, two leading myeloma experts discuss key questions and controversies arising from the rapid validation of novel therapeutics for patients with MM who are autologous stem cell transplantation (ASCT) eligible. Although the use of ASCT remains a core therapeutic modality for MM, using ASCT in conjunction with innovative treatment options—including CAR-T cell therapy, proteasome inhibitors, immunomodulators, and antibodies such as, CD38 antibodies, BCMA-targeting antibody-drug conjugates, and bispecific antibodies—can substantially improve outcomes. These improvements have been observed across the continuum of care, from primary therapy to the management of relapsed/refractory disease (post-ASCT), as well as in the setting of minimal residual disease eradication. Hear our expert panel as they highlight these improvements and discuss the integration of approved and emerging novel therapies in MM. Upon completion of this activity, participants should be better able to: List current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in various multiple myeloma treatment settings, Describe efficacy and safety data surrounding novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new targeted agent classes in the management of ASCT-eligible patients with multiple myeloma, Develop regimens with novel components for ASCT-eligible patients with multiple myeloma, including as induction/consolidation or maintenance therapy, or in the setting of early relapse or refractory myeloma.

Mar 8

59 min 32 sec

Go online to PeerView.com/QUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert panel of hematologists, oncologists, and a patient advocate discuss compelling, real-world case scenarios and the practice-changing evidence that continues to support the increasing role of novel therapeutics in CLL. This event also explores the future of CLL care and illustrates how novel combinations and cellular therapy may lead to deep, durable, and minimal residual disease-negative responses. Upon completion of this activity, participants should be better able to: Cite genetic/molecular, clinical, or patient-related factors that can guide therapeutic selection in patients with treatment-naïve or relapsed/refractory CLL, Summarize current safety and efficacy evidence and practice guideline recommendations related to the use of novel therapeutics, including BTK, PI3K, and BCL-2 inhibitors and novel antibodies across the spectrum of CLL, Select personalized initial or sequential treatment regimens with novel components for patients with treatment-naïve or relapsed CLL, Manage the unique spectrum of adverse events associated with the use of novel therapies in patients with CLL, Educate patients with CLL about treatment expectations, unique toxicity profiles, and dosing/adherence considerations with novel therapeutics.

Jan 29

1 hr 36 min

Go online to PeerView.com/FSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As precision medicine has taken a varying course in the setting of hematologic cancers, safely integrating effective, novel therapeutics into the management of patients whose cancers express markers such as CD30 and CD123 is more important than ever. In this activity, our experts discuss the diagnostic and treatment implications of these markers in various hematologic disease settings and use workshop-style educational segments with patient cases and clinical scenarios to illustrate the medical benefits of precision medicine for hematologic cancers defined by CD30 and CD123 expressions. Upon completion of this activity, participants should be better able to: Describe the significance of CD30 and CD123 in a range of hematologic cancers, including implications for diagnosis, immunophenotypic/molecular testing, and prognosis, Cite current efficacy and safety evidence on the use of novel therapeutics in CD30-expressing lymphoma, including in patients with newly diagnosed or relapsed disease, Discuss current evidence on the use of CD123-targeting agents in a range of hematologic cancers characterized by CD123 expression, Integrate novel therapeutics into the management of patients with newly diagnosed or relapsed/refractory Hodgkin or T-cell lymphoma, blastic plasmacytoid dendritic cell neoplasm, and chronic myelomonocytic leukemia, Manage safety considerations associated with the use of novel therapeutics in patients with CD30- or CD123-expressing malignancies.

Jan 22

1 hr 32 min

Go online to PeerView.com/XNY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in chronic rhinosinusitis with nasal polyps discusses novel and emerging biologic therapies to improve the quality of life for patients with chronic rhinosinusitis with nasal polyps. Upon completion of this activity, participants should be better able to: Recognize the burden that chronic rhinosinusitis with nasal polyps (CRS/NP) on patient quality of life, Describe the pathophysiology of CRS/NP and its relevance to novel therapeutic targets, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRS/NP, Apply individualized treatment plans, including the use of targeted biologic therapy, for patients with CRS/NP inadequately controlled on standard therapy.

Jan 12

30 min 43 sec

Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton’s tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, researchers continue to assess the potential of BCL-2 targeting agents and BTK inhibitor combinations, while new science has led to the regulatory approval of chimeric antigen receptor (CAR)-T cell therapy in relapsed disease. In this “Clinical Consults” activity, experts will offer guidance on key findings that have decisively turned the field away from chemotherapy-centric care. Upon completion of this activity, participants should be better able to: Summarize current recommendations for managing newly diagnosed and relapsed/refractory MCL based on factors such as treatment history, disease characteristics, or need for aggressive therapy, Discuss evidence surrounding novel treatment regimens that include BTK inhibitor, BCL-2 inhibitor, immunomodulatory, or adoptive cell therapy components across the MCL disease spectrum, Recommend therapy with novel components for the management of patients with MCL after consideration of baseline prognostic factors and/or treatment history, Manage the unique spectrum of adverse events associated with novel therapeutics in patients with MCL.

Jan 11

1 hr 1 min

Go online to PeerView.com/VAY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading hematology-oncology experts discuss the most recent clinical evidence supporting modern antibody options in acute lymphoblastic leukemia (ALL), explore their increasing therapeutic applications, and gauge the progress in improving patient outcomes across a range of ALL populations and treatment settings. Upon completion of this activity, participants should be better able to: Discuss current practice guidelines illustrating the role of antibody therapy in the management of newly diagnosed or relapsed/refractory ALL, including in Ph-negative or -positive disease, as a pretransplant strategy, or in patients with residual disease, Cite current evidence surrounding innovative antibody-based approaches, including antibody–drug conjugates and bispecific antibodies, in the management of ALL, Select evidence-based regimens with antibody components for the management of patients with ALL, Manage safety considerations related to the use of antibody therapy in patients with Ph-negative or -positive ALL.

Jan 8

1 hr 34 min

Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Cite molecular-, disease-, or patient-related factors that can guide therapeutic selection and prognosis in patients with FL or DLBCL, Summarize current safety and efficacy evidence surrounding novel therapeutic classes, including targeted/epigenetic agents, IMiDs, antibodies, and CAR-T cell therapy, used to treat FL or DLBCL, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory FL or DLBCL with consideration of baseline risk factors and patient/disease characteristics, Develop a management plan for the unique adverse events associated with the use of novel therapies in patients with FL or DLBCL.

Jan 8

1 hr 25 min

Go online to PeerView.com/KGQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an asthma expert discusses the relationship between type 2 inflammation and moderate to severe asthma and the use of targeted biologic therapies as treatment. Upon completion of this activity, participants should be better able to: Explain the relationship between type 2 inflammation and moderate-to-severe asthma, biomarkers such as blood eosinophils, and other comorbid conditions, Identify patients with uncontrolled moderate-to-severe asthma who are eligible for targeted biologic therapies based on clinical characteristics of type 2 inflammation, Develop treatment plans for patients with uncontrolled moderate-to-severe asthma according to updated evidence-based guidelines and the latest clinical data on efficacy and safety regarding targeted biologic therapy.

Jan 7

25 min 48 sec

Go online to PeerView.com/DKK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multisystemic disorder that can be fatal if left untreated. EGPA is characterized by moderate-to-severe asthma, peripheral blood eosinophilia, mononeuropathy or polyneuropathy, pulmonary infiltrates, paranasal sinus abnormalities, and extravascular eosinophils or eosinophilic vasculitis. Optimal treatment involves accurate diagnosis of the condition, keeping abreast of novel and emerging therapies, and a multidisciplinary approach. This web broadcast features two experts in EGPA as they aim to give a greater understanding into the recognition, diagnosis, and individualized management of EGPA. The event concludes with a practicum discussion to connect the data with real-life application. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of eosinophilic granulomatosis with polyangiitis (EGPA) and its relationship to novel therapeutic targets, Recognize the importance of a multidisciplinary approach in diagnosing and managing patients with EGPA, Apply evidence-based approaches to diagnose and differentiate EGPA from other eosinophilic disorders, Develop individualized treatment plans for patients with EGPA based on the latest clinical data.

Jan 6

1 hr

Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.

Jan 4

1 hr 39 min

Go online to PeerView.com/QBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME/MOC-accredited video activity, Josep Tabernero, MD, PhD, gives his perspective on the latest evidence on novel HER2-targeted and other molecular-directed therapies in gastric cancer. Hear about recent data presented on gastric cancer and how precision medicine may improve gastric cancer patient care. Upon completion of this activity, participants should be better able to: Review the biologic rationale for targeting molecular signatures of gastric cancer, such as HER2 or PD-L1 overexpression, Examine expert and guideline-based biomarker testing recommendations in gastric cancer that can guide optimal treatment selection, Assess the latest safety and efficacy evidence of novel therapeutics for gastric cancer, such as checkpoint inhibitors, cytotoxic agents, and HER2-directed antibody-drug conjugates, Develop safe and effective validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.

Nov 2020

35 min 26 sec

Go online to PeerView.com/KXJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss strategies to provide optimal care to individual patients with chronic spontaneous urticaria in the context of an advancing treatment landscape. A patient also joins the discussion to provide unique perspectives on living with chronic spontaneous urticaria and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Recognize physical exam findings and symptomatology suggestive of chronic spontaneous urticaria (CSU), Apply evidence-based diagnostic testing and laboratory evaluation, Employ a guideline-driven approach to the treatment of CSU, Identify patients with refractory disease in whom treatment intensification is warranted, Assess efficacy and safety data related to emerging treatment options for CSU, Recognize the importance of collaboration between specialists and primary care providers to provide optimal treatment and longitudinal support for patients with CSU.

Nov 2020

39 min 51 sec

Go online to PeerView.com/JZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, so has the importance of predictive biomarkers to guide clinical decisions and identify patients who are most likely to benefit from specific immune checkpoint inhibitors or combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, TMB, LAG-3, and others. Pathologists play an essential role in carrying out appropriate testing for these biomarkers. This onDemand activity based on a recent live PeerView Virtual Seminar and Workshop provides pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminar segments, an expert panel reviews evidence on current and emerging immunotherapies and biomarkers, and the Workshop segments focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals to interpret biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest evidence on established/emerging biomarkers (including PD-L1, MSI/MMR, and TMB, among others) and the rationale for their use to predict benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cutpoints, and other nuances, Apply the latest evidence and recommendations for cancer immunotherapy biomarker testing in community and academic settings, Implement effective strategies for interdisciplinary collaboration and coordination among pathologists, oncologists, and other key professionals regarding selection and interpretation of immunotherapy biomarker tests to guide clinical decision-making in immuno-oncology.

Nov 2020

59 min 46 sec

Go online to PeerView.com/BYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC-accredited video activity Professor David I. Marks, Farhad Ravandi, MD, and Matthias Stelljes, MD, give insights on the evidence behind the emergence of antibody therapy and its use in conjunction with HSCT in AML and ALL. These scientific MasterClass sessions are paired with a case-centered segment that illustrates therapeutic nuances such as the identification of transplant-eligible patients who may benefit from antibody-enhanced treatment protocols and the management of safety considerations unique to the use of antibodies in HSCT populations. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction/consolidation, pretransplant conditioning, or other roles in conjunction with transplant in the acute leukemia setting, Summarize updated evidence surrounding innovative antibody-based approaches to induction/consolidation, conditioning, or post-HSCT therapy in patients with AML or ALL, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HSCT for patients with AML or ALL, Manage safety considerations related to the use of antibody therapy in transplant-eligible populations with acute leukemia.

Nov 2020

1 hr 29 min

Go online to PeerView.com/GKC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapies are addressing a big unmet need in triple-negative breast cancer (TNBC) due to limited treatment options, the aggressive nature of the disease, and poor patient outcomes. This PeerView Live MasterClass and Practicum provides a comprehensive overview of the evolving role of immune checkpoint inhibitors in TNBC, specifically directed to surgeons. Experts explain the biologic rationale for the use of cancer immunotherapies in TNBC and explore the clinical evidence supporting their use in advanced/metastatic TNBC, as well as neoadjuvant/adjuvant settings of early-stage TNBC. Additionally, the faculty provides guidance on the practicalities of patient/tumor evaluation and candidate selection for immunotherapies, including their use in the context of other treatment modalities, and detection and management of immune-related adverse events. Strategies for effective collaboration and coordination of care among surgeons, oncologists, and other specialists in the era of immuno-oncology are also shared. Upon completion of this activity, participants should be better able to: Review the biologic rationale and rational strategies for harnessing the immune system in the treatment of triple-negative breast cancer (TNBC), including combinatorial or sequential approaches with immune checkpoint inhibitors and other effective therapies that may enhance immunogenicity and improve outcomes, Evaluate the efficacy, safety, biomarker, and other key data from clinical trials assessing immunotherapy and immune-based combinations or sequential strategies with other effective treatment modalities throughout the continuum of TNBC, including early-stage (neoadjuvant/adjuvant settings) and advanced/metastatic disease, Integrate immunotherapies into treatment plans for patients with TNBC based on the latest evidence, indications, recommendations, disease stage/treatment setting, patient and tumor characteristics, and other relevant factors in the context of effective multidisciplinary collaboration.

Nov 2020

1 hr 3 min

Go online to PeerView.com/YHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME video activity, experts in systemic lupus erythematosus (SLE) give a detailed discussion on the autoimmune disease, providing guidance on recognizing the clinical features and confirming a diagnosis, as well as contemporary strategies to manage diverse disease manifestations. Hear what the experts are doing in their clinics. Upon completion of this activity, participants should be better able to: Identify systemic lupus erythematosus (SLE) as a heterogeneous autoimmune disease with a wide range of clinical and serological manifestations that can affect any organ, Employ appropriate criteria to confirm a diagnosis of SLE, recognizing the clinical utility of available classification systems, Utilize evidence-based tools to monitor disease activity in individual SLE patients in daily clinical practice and guide treatment decisions, Describe current treatment options for SLE according to mechanism of action, efficacy, safety, and impact on patient symptoms/quality of life, Develop treatment plans for individual patients with SLE to control disease activity and prevent or minimize disease flares, drug toxicity, and organ damage, Effectively communicate and collaborate with SLE patients and other care providers to understand and address the needs of each patient and maximize treatment adherence, quality of life, and survival outcomes.

Oct 2020

1 hr 11 min

Go online to PeerView.com/ZHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatic diseases discusses strategies to select and optimize treatment for individual patients with RA and PsA, focusing on the appropriate clinical utilization of newer treatment options (ie, JAK inhibitors). Upon completion of this activity, participants will be able to: Outline advances that have improved the quality of care in rheumatic diseases, Explain the role of the JAK/STAT signaling pathway in the pathophysiology of RA and PsA, Summarize efficacy and safety data related to current JAK inhibitors for the treatment of RA and PsA, Treat RA and PsA in accordance with current evidence and guidelines, recognizing the role of non-anti-TNF therapies in patients with active disease, Incorporate JAK inhibitors into treatment plans for individual patients with RA or PsA, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.

Sep 2020

24 min 43 sec

Go online to PeerView.com/PHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of triple-negative breast cancer (TNBC) has remained challenging for many years, with limited effective options and poor outcomes for most patients. But the tide is turning, as new therapies are emerging for this patient population, with immunotherapy representing a new pillar of care in the treatment of TNBC. TNBC is known to be more immunogenic compared with other breast cancer subtypes, and thus, immunotherapy has been and continues to be extensively explored in TNBC. Clinical trials have started to show promising results in both advanced and early-stage TNBC; the first combination of an immune checkpoint inhibitor and chemotherapy has been approved by the FDA for the first-line treatment of PD-L1+ TNBC, and it is likely that the treatment landscape will continue to expand. In this educational on-demand activity based on a recent live web broadcast, a panel of leading experts discusses the current and emerging roles of immunotherapy in TNBC as well as the clinical trial data assessing immunotherapies and immune-based combinations throughout the continuum of TNBC. The practical nuances of patient selection, treatment integration, biomarker testing, and immune-related adverse event management are also explored. Upon completion of this activity, participants should be better able to: Discuss the rationale for use of cancer immunotherapies in the treatment of triple-negative breast cancer (TNBC) specifically and breast cancer more broadly, Assess efficacy, safety, and other key data from clinical trials assessing immunotherapies and immune-based combinations throughout the continuum of TNBC, including in metastatic settings as well as in early-stage disease in neoadjuvant or adjuvant settings, and relevant implications for clinical practice, Evaluate the current and emerging role of immunotherapies in TNBC, nuances of patient selection and treatment integration, biomarker testing when relevant, management of immune-related adverse events, and other practical aspects related to their use in clinical practice, Integrate immune checkpoint inhibitors into treatment plans of patients with TNBC based on latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, and patient needs/preferences.

Sep 2020

1 hr 4 min

Go online to PeerView.com/KFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Dr. Heather McArthur provides a brief recap of how the emergence of checkpoint inhibitor therapy in TNBC has changed the management of this challenging subtype of breast cancer, and what some of the unanswered questions and controversies are that ongoing research is aiming to answer. Upon completion of this activity, participants should be better able to: Discuss the rationale for use of cancer immunotherapies in the treatment of triple-negative breast cancer (TNBC) specifically and breast cancer more broadly, Assess efficacy, safety, and other key data from clinical trials assessing immunotherapies and immune-based combinations throughout the continuum of TNBC, including in metastatic settings as well as in early-stage disease in neoadjuvant or adjuvant settings, and relevant implications for clinical practice, Evaluate the current and emerging role of immunotherapies in TNBC, nuances of patient selection and treatment integration, biomarker testing when relevant, management of immune-related adverse events, and other practical aspects related to their use in clinical practice, Integrate immune checkpoint inhibitors into treatment plans of patients with TNBC based on latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, and patient needs/preferences.

Sep 2020

31 min 5 sec

Go online to PeerView.com/RXX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pulmonology discusses key issues in the diagnosis and treatment of patients with uncontrolled persistent asthma. Several case vignettes provide insights on assessing phenotype/endotype and eligibility for biologic therapy in these patients, in the context of common comorbidities and other patient-, disease-, and treatment-related factors. Upon completion of this activity, participants should be better able to: Describe the role of the type 2 inflammatory cascade in uncontrolled persistent asthma and the implications for treatment, Evaluate patients with asthma for symptom severity, phenotype/endotype, exacerbation risk, and eligibility for biologic therapies, Employ the latest clinical data on efficacy and safety of biologic therapies to the treatment of patients with uncontrolled persistent asthma, Use strategies to engage patients in shared decision-making to improve outcomes and quality of life.

Sep 2020

39 min 46 sec

Go online to PeerView.com/VBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC-accredited video activity, Josep Tabernero, MD, PhD; Geoffrey Ku, MD; and Kohei Shitara, MD, synthesize the latest data of emerging and available novel therapies and consider the future of gastric cancer care. These experts also examine best practices for testing biomarkers such as HER2, PD-L1, and MSI, and provide guidance on integrating scientific advances and novel therapeutics into sound, evidence-based management strategies to improve outcomes for patients with gastric cancer. Upon completion of this activity, participants should be better able to: Review the biologic rationale for targeting molecular signatures of gastric cancer, such as HER2 or PD-L1 overexpression, Examine expert and guideline-based biomarker testing recommendations in gastric cancer that can guide optimal treatment selection, Assess the latest safety and efficacy evidence of novel therapeutics for gastric cancer, such as checkpoint inhibitors, cytotoxic agents, and HER2-directed antibody-drug conjugates, Develop safe and effective validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.

Aug 2020

58 min 49 sec

Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

Aug 2020

1 hr 1 min

Go online to PeerView.com/FDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CNE activity, a family nurse practitioner brings the nurse’s perspective to patient care in endometrial and cervical cancer. Kimberly Halla, MSN, FNP-C, discusses modern management techniques for patient’s receiving targeted therapy and immunotherapy, as well as combination therapies, and gives her take on how to approach the unique safety profiles associated with these treatment options. Upon completion of this activity, participants will be able to: Summarize the current treatment and regulatory landscape in the management of gynecologic cancers, including the role of novel targeted, immunotherapeutic, and combination approaches in cervical and endometrial cancers, Describe safety and efficacy evidence surrounding targeted, immune checkpoint inhibitor, and combination strategies for the management of gynecologic cancers, Educate patients about therapeutic and safety considerations associated with recently approved and emerging options for endometrial and cervical cancers, Manage the unique spectrum of adverse events associated with targeted and immunotherapy used to treat endometrial and cervical cancers.

Jul 2020

35 min 49 sec

Go online to PeerView.com/WHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The evidence base for use of immunotherapy in lung cancer is expanding at a rapid pace, and immune checkpoint inhibition has become a new standard of care after chemoradiation in stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC). The effectiveness of immunotherapy as a component of multimodal therapy has raised the possibility of further expanding this treatment approach to earlier stages of lung cancer, including as neoadjuvant or adjuvant therapy for patients with resectable disease. A range of novel single-agent and combination immunotherapeutic approaches are being explored, and results are eagerly anticipated. However, many challenges and questions related to the optimal use of immunotherapies in earlier stages of lung cancer remain. For example, which patients are most likely to benefit from immune-based therapies? What is the optimal way to individualize therapy and coordinate care among different specialists, including thoracic surgeons, radiation oncologists, and medical oncologists? How should the various adverse effects associated with these emerging treatment modalities be managed? This educational on-demand activity based on a recent live webcast features expert instruction and practical guidance for how to effectively navigate the rapidly changing and complex immunotherapy landscape in lung cancer, including in earlier disease settings as a component of multimodal therapy. Access the activity to learn more about this timely, important topic, and what the implications are for clinical practice. Upon completion of this activity, participants should be better able to: Characterize the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies, and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, Discuss the current and evolving immunotherapy landscape and state of the science in lung cancer, including in locally advanced and earlier stages of NSCLC, Review key clinical trials assessing immunotherapies and immune-based combinations in stage III and earlier stages of lung cancer, and available data from such trials, Determine the best treatment approaches for patients with stage III or earlier stages of lung cancer as part of clinical practice or clinical trials based on the latest evidence, recommendations, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care.

Jul 2020

1 hr 6 min

Go online to PeerView.com/WCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Suresh S. Ramalingam, MD, FACP, FASCO, provides a brief recap of the latest practice-changing data informing the use of an expanding arsenal of immune checkpoint inhibitors and combinations in NSCLC, as well as the evolving evidence on immunotherapies, transcription inhibitors, and other novel treatment approaches in SCLC. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.

Jul 2020

28 min 4 sec

Go online to PeerView.com/KAS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hematology discusses the recognition, classification, and treatment of adult and pediatric patients with veno-occlusive disease and sinusoidal obstruction syndrome. Upon completion of this activity, participants should be better able to: Cite updated recommendations and evidence on veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) risk factors, diagnostic criteria, and disease severity grading, Establish a diagnosis of VOD/SOS, including late-onset disease, and VOD/SOS with or without organ dysfunction in adult and pediatric populations, Recommend effective, timely treatment for patients with confirmed VOD/SOS, including those presenting with or without organ dysfunction.

Jul 2020

40 min 32 sec

Go online to PeerView.com/TYJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Brendon Stiles, MD, provides a brief recap of the latest advances in the use of immunotherapy as a component of multimodal lung cancer care in locally advanced and earlier stages of NSCLC. He highlights some of the newest data from clinical trials and shares his perspective on the promise and implications of the transition of immune checkpoint inhibitor therapy into curative intent settings of lung cancer. Upon completion of this activity, participants should be better able to: Characterize the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies, and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, Discuss the current and evolving immunotherapy landscape and state of the science in lung cancer, including in locally advanced and earlier stages of NSCLC, Review key clinical trials assessing immunotherapies and immune-based combinations in stage III and earlier stages of lung cancer, and available data from such trials, Determine the best treatment approaches for patients with stage III or earlier stages of lung cancer as part of clinical practice or clinical trials based on the latest evidence, recommendations, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care.

Jun 2020

36 min 50 sec

Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.

Jun 2020

1 hr 39 min